Cargando…

Plasma mannose as a novel marker of myocardial infarction across different glycaemic states: a case control study

BACKGROUND: Plasma mannose, an emerging novel biomarker of insulin resistance, is associated with both diabetes mellitus and coronary atherosclerosis, but the relationship between mannose concentrations and myocardial infarction (MI) across different glycaemic states remains to be elucidated. The ai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fortin, Elena, Ferrannini, Giulia, Campi, Beatrice, Mellbin, Linda, Norhammar, Anna, Näsman, Per, Saba, Alessandro, Ferrannini, Ele, Rydén, Lars
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508730/ https://www.ncbi.nlm.nih.gov/pubmed/36151569 http://dx.doi.org/10.1186/s12933-022-01630-5

Ejemplares similares

Empagliflozin improves insulin sensitivity in patients with recent acute coronary syndrome and newly detected dysglycaemia: Experiences from the randomized, controlled SOCOGAMI trial
por: Fortin, Elena, et al.
Publicado: (2023)

Mannose-binding lectin does not explain the dismal prognosis after an acute coronary event in dysglycaemic patients. A report from the GAMI cohort
por: Meziani, Sara, et al.
Publicado: (2022)

Androgen receptor polymorphism, testosterone levels, and prognosis in patients with acute myocardial infarction
por: Wang, Anne, et al.
Publicado: (2021)

Antiphospholipid antibodies in patients with dysglycaemia: A neglected cardiovascular risk factor?
por: Ferrannini, Giulia, et al.
Publicado: (2020)

Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveys
por: Ferrannini, Giulia, et al.
Publicado: (2021)

Mannose-Binding Lectin Genotype and Phenotype in Patients With Type 2 Diabetes and Myocardial Infarction: A report from the DIGAMI 2 trial
por: Mellbin, L.G., et al.
Publicado: (2010)

Liver function markers predict cardiovascular and renal outcomes in the CANVAS Program
por: Ferrannini, Giulia, et al.
Publicado: (2022)

Plasma N-Acetylaspartate Is Related to Age, Obesity, and Glucose Metabolism: Effects of Antidiabetic Treatment and Bariatric Surgery
por: Daniele, Giuseppe, et al.
Publicado: (2020)

Response to Comment on: Ferrannini. Learning From Glycosuria. Diabetes 2011;60:695–696
por: Ferrannini, Ele
Publicado: (2011)

Learning From Glycosuria
por: Ferrannini, Ele
Publicado: (2011)

A Journey in Diabetes: From Clinical Physiology to Novel Therapeutics: The 2020 Banting Medal for Scientific Achievement Lecture
por: Ferrannini, Ele
Publicado: (2021)

Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
por: Ferrannini, Giulia, et al.
Publicado: (2015)

Extremes of both weight gain and weight loss are associated with increased incidence of heart failure and cardiovascular death: evidence from the CANVAS Program and CREDENCE
por: Ferrannini, Giulia, et al.
Publicado: (2023)

Impact of Different Bariatric Surgical Procedures on Insulin Action and β-Cell Function in Type 2 Diabetes
por: Ferrannini, Ele, et al.
Publicado: (2009)

Anti-inflammatory properties of antidiabetic drugs: A “promised land” in the COVID-19 era?
por: Katsiki, Niki, et al.
Publicado: (2020)

Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye?
por: Ferrannini, Ele, et al.
Publicado: (2021)

Role of anatomical location, cellular phenotype and perfusion of adipose tissue in intermediary metabolism: A narrative review
por: Camastra, Stefania, et al.
Publicado: (2022)

Erratum. Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye? Diabetes Care 2021;44:641–646
por: Ferrannini, Ele, et al.
Publicado: (2021)

Copeptin, IGFBP-1, and Cardiovascular Prognosis in Patients With Type 2 Diabetes and Acute Myocardial Infarction: A report from the DIGAMI 2 trial
por: Mellbin, Linda G., et al.
Publicado: (2010)

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes
por: Polidori, David, et al.
Publicado: (2014)

Redefining the Diagnosis of Diabetes Using Glycated Hemoglobin
por: Fonseca, Vivian, et al.
Publicado: (2009)

Human Insulin Resistance Is Associated With Increased Plasma Levels of 12α-Hydroxylated Bile Acids
por: Haeusler, Rebecca A., et al.
Publicado: (2013)

Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence
por: Natali, Andrea, et al.
Publicado: (2021)

Differential Proteomics of Cardiovascular Risk and Coronary Artery Disease in Humans
por: Ferrannini, Ele, et al.
Publicado: (2022)

Renal Glucose Handling: Impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes
por: Ferrannini, Ele, et al.
Publicado: (2013)

Fixed‐ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß‐cell function in people with type 2 diabetes
por: Ferrannini, Ele, et al.
Publicado: (2022)

Metabolomic Profile Predicts Development of Microalbuminuria in Individuals with Type 1 Diabetes
por: Haukka, Jani K., et al.
Publicado: (2018)

Progression to Diabetes in Relatives of Type 1 Diabetic Patients: Mechanisms and Mode of Onset
por: Ferrannini, Ele, et al.
Publicado: (2010)

Mannose-Binding Lectin Deficiency Is Associated with Myocardial Infarction: The HUNT2 Study in Norway
por: Vengen, Inga Thorsen, et al.
Publicado: (2012)

New Trial Evidence on Heart Failure: Highlights from the European Society of Cardiology Congress 2021
por: Ferrannini, Giulia, et al.
Publicado: (2022)

Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial
por: Ferrannini, Ele, et al.
Publicado: (2010)

Short Course of Insulin Treatment versus Metformin in Newly Diagnosed Patients with Type 2 Diabetes
por: Seghieri, Marta, et al.
Publicado: (2018)

Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea
por: Shin, Yujin, et al.
Publicado: (2020)

The effect of age on longitudinal measures of beta cell function and insulin sensitivity during the progression of early stage type 1 diabetes
por: Ferrannini, Ele, et al.
Publicado: (2022)

β-Cell Glucose Sensitivity to Assess Changes in β-Cell Function in Recent-Onset Stage 3 Type 1 Diabetes
por: Gitelman, Stephen E., et al.
Publicado: (2023)

Anti-inflammatory and Antioxidant Properties of HDLs Are Impaired in Type 2 Diabetes
por: Morgantini, Cecilia, et al.
Publicado: (2011)

Decreased expression of hepatic glucokinase in type 2 diabetes
por: Haeusler, Rebecca A., et al.
Publicado: (2014)

IgG N-Glycosylation Is Altered in Coronary Artery Disease
por: Radovani, Barbara, et al.
Publicado: (2023)

Complement Activation and Prognosis in Patients With Type 2 Diabetes and Myocardial Infarction: A report from the DIGAMI 2 trial
por: Mellbin, Linda G., et al.
Publicado: (2012)

Long-term impact of postconditioning on infarct size and left ventricular ejection fraction in patients with ST-elevation myocardial infarction
por: Sörensson, Peder, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_mlssqbnh0m924en7mvacn42esj